RhumbLine Advisers’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$173M Sell
2,213,044
-28,248
-1% -$2.28M 0.13% 113
2026
Q1
$194M Sell
2,241,292
-40,246
-2% -$3.86M 0.17% 95
2025
Q4
$219M Sell
2,281,538
-60,820
-3% -$5.91M 0.18% 89
2025
Q3
$223M Sell
2,342,358
-19,934
-0.8% -$1.83M 0.18% 92
2025
Q2
$206M Sell
2,362,292
-39,315
-2% -$3.33M 0.18% 94
2025
Q1
$216M Sell
2,401,607
-141,331
-6% -$12.6M 0.2% 86
2024
Q4
$203M Buy
2,542,938
+7,596
+0.3% +$658K 0.18% 90
2024
Q3
$228M Sell
2,535,342
-103,258
-4% -$8.69M 0.21% 79
2024
Q2
$208M Buy
2,638,600
+391
+0% +$32.1K 0.2% 87
2024
Q1
$230M Sell
2,638,209
-20,887
-0.8% -$1.78M 0.22% 81
2023
Q4
$219M Sell
2,659,096
-22,411
-0.8% -$1.71M 0.23% 80
2023
Q3
$210M Buy
2,681,507
+13,950
+0.5% +$1.17M 0.24% 71
2023
Q2
$235M Buy
2,667,557
+29,845
+1% +$2.57M 0.26% 63
2023
Q1
$213M Buy
2,637,712
+89,648
+4% +$7.31M 0.26% 70
2022
Q4
$198M Buy
2,548,064
+131,539
+5% +$10.7M 0.27% 75
2022
Q3
$195M Buy
2,416,525
+57,210
+2% +$5.14M 0.29% 63
2022
Q2
$212M Buy
2,359,315
+94,365
+4% +$9.56M 0.31% 58
2022
Q1
$251M Buy
2,264,950
+93,462
+4% +$9.87M 0.32% 51
2021
Q4
$225M Buy
2,171,488
+54,698
+3% +$6.33M 0.28% 64
2021
Q3
$265M Sell
2,116,790
-50,125
-2% -$6.49M 0.36% 47
2021
Q2
$269M Sell
2,166,915
-102,718
-5% -$12.9M 0.35% 47
2021
Q1
$268M Sell
2,269,633
-139,885
-6% -$16.4M 0.36% 47
2020
Q4
$282M Buy
2,409,518
+8,301
+0.3% +$914K 0.39% 46
2020
Q3
$250M Sell
2,401,217
-72,015
-3% -$7.23M 0.39% 48
2020
Q2
$227M Buy
2,473,232
+88,436
+4% +$8.48M 0.38% 49
2020
Q1
$215M Buy
2,384,796
+44,797
+2% +$4.77M 0.45% 38
2019
Q4
$265M Buy
2,339,999
+23,553
+1% +$2.58M 0.44% 35
2019
Q3
$252M Buy
2,316,446
+60,662
+3% +$6.33M 0.46% 34
2019
Q2
$220M Sell
2,255,784
-46,569
-2% -$4.25M 0.41% 38
2019
Q1
$210M Sell
2,302,353
-84,838
-4% -$7.59M 0.41% 42
2018
Q4
$217M Buy
2,387,191
+50,038
+2% +$4.68M 0.47% 34
2018
Q3
$230M Sell
2,337,153
-60,133
-3% -$5.56M 0.44% 40
2018
Q2
$205M Sell
2,397,286
-49,758
-2% -$4.16M 0.41% 42
2018
Q1
$196M Buy
2,447,044
+3,781
+0.2% +$312K 0.41% 42
2017
Q4
$197M Buy
2,443,263
+27,156
+1% +$2.17M 0.4% 44
2017
Q3
$188M Buy
2,416,107
+55,903
+2% +$4.64M 0.41% 43
2017
Q2
$209M Buy
2,360,204
+3,031
+0.1% +$256K 0.48% 37
2017
Q1
$190M Buy
2,357,173
+122,793
+5% +$9.59M 0.44% 37
2016
Q4
$159M Buy
2,234,380
+89,810
+4% +$7.06M 0.4% 41
2016
Q3
$185M Buy
2,144,570
+71,083
+3% +$6.19M 0.51% 35
2016
Q2
$180M Buy
2,073,487
+122,326
+6% +$9.89M 0.53% 34
2016
Q1
$146M Buy
1,951,161
+132,955
+7% +$10M 0.45% 40
2015
Q4
$140M Buy
1,818,206
+2,980
+0.2% +$224K 0.45% 40
2015
Q3
$122M Sell
1,815,226
-77,176
-4% -$5.68M 0.41% 45
2015
Q2
$140M Sell
1,892,402
-386,604
-17% -$29.5M 0.45% 42
2015
Q1
$178M Buy
2,279,006
+546,463
+32% +$41.4M 0.51% 37
2014
Q4
$125M Sell
1,732,543
-43,286
-2% -$3.01M 0.36% 56
2014
Q3
$110M Sell
1,775,829
-58,437
-3% -$3.72M 0.33% 60
2014
Q2
$117M Sell
1,834,266
-49,117
-3% -$2.98M 0.34% 57
2014
Q1
$116M Sell
1,883,383
-62,299
-3% -$3.63M 0.34% 57
2013
Q4
$112M Sell
1,945,682
-72,529
-4% -$4.11M 0.33% 59
2013
Q3
$107M Buy
2,018,211
+6,683
+0.3% +$360K 0.33% 59
2013
Q2
$104M Buy
+2,011,528
New +$99.4M 0.33% 59

Other funds holding MDT

RhumbLine Advisers's MDT Position: Q2 2026 in Review

RhumbLine Advisers reduced its Medtronic (MDT) stake by 1.3% in Q2 2026, selling an estimated $2.28M and leaving 2,213,044 shares worth $173M. The position accounts for 0.13% of the portfolio, ranked #113.

RhumbLine Advisers first reported a position in MDT in Q2 2013 and has held it in 53 quarters since. The position peaked at $282M in Q4 2020. 2,128 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • RhumbLine Advisers held 2,213,044 shares of Medtronic worth $173M as of Q2 2026.
  • RhumbLine Advisers sold 28,248 Medtronic shares in Q2 2026, an estimated $2.28M.
  • Medtronic made up 0.13% of RhumbLine Advisers's portfolio in Q2 2026, its #113 holding.
  • RhumbLine Advisers first reported a position in Medtronic in Q2 2013 and has held it in 53 quarters since.
  • RhumbLine Advisers's Medtronic position peaked at $282M in Q4 2020.
  • 2,128 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.